Modular Domains of Host Proteins Regulate Filovirus Maturation

宿主蛋白的模块化结构域调节丝状病毒成熟

基本信息

  • 批准号:
    9517218
  • 负责人:
  • 金额:
    $ 24.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-01-15 至 2019-12-31
  • 项目状态:
    已结题

项目摘要

The ultimate goal of this proposal is to elucidate the novel antiviral mechanism of host BAG3; a newly discovered filovirus VP40 interacting protein that inhibits viral egress. Filoviruses (Ebola [EBOV] and Marburg [MARV]) are Category A, high-priority pathogens, for which there are no commercially available vaccines or therapeutic agents. Thus, exploratory and innovative approaches are warranted to better understand viral-host interactions that both promote and inhibit the transmission of these deadly viruses. Our laboratory focuses on the mechanisms by which filoviruses interact with and recruit host proteins to regulate the budding process. Here, we identified an unanticipated interaction between filovirus VP40 and the host protein BAG3. BAG3 is a stress-regulated, co-chaperone protein whose function is to ensure cell survival and protein homeostasis via Chaperone-Assisted Selective Autophagy (CASA). While BAG3 has been shown to positively influence entry and replication for some viruses, we found that the interaction of the PPxY motif of both EBOV and MARV VP40 with the single N-terminal WW-domain of BAG3 leads to an unexpected decrease in egress of both EBOV and MARV VP40 virus-like particles (VLPs), as well as VSV recombinant viruses that serve as functional EBOV surrogates, as they are genetically engineered to express either EBOV VP40 WT or mutant L-domains in place of the L-domain of VSV M. We hypothesize that BAG3 expression is induced following filovirus infection, and that BAG3 targets VP40 for removal and/or sequestration from the site of budding at the plasma membrane. We will use a rigorous multifaceted approach to interrogate the mechanisms by which BAG3 disrupts virus particle egress, thus providing new insight into the potential role of CASA as a novel and specific host defense strategy to counteract the ability of VP40 to promote efficient egress and spread of virus particles.
该提案的最终目标是阐明宿主BAG 3的新的抗病毒机制; 发现丝状病毒VP 40相互作用蛋白,抑制病毒外出。丝状病毒(埃博拉病毒[EBOV]和 马尔堡[MARV])是A类高优先级病原体,目前尚无市售产品 疫苗或治疗剂。因此,有必要采取探索性和创新性办法, 了解促进和抑制这些致命病毒传播的病毒-宿主相互作用。 我们的实验室专注于丝状病毒与宿主蛋白相互作用并招募宿主蛋白的机制, 调节萌芽过程。在这里,我们确定了丝状病毒VP 40和 宿主蛋白BAG 3。BAG 3是一种应激调节的共分子伴侣蛋白,其功能是确保细胞凋亡。 通过伴侣辅助的选择性自噬(CASA)的存活和蛋白质稳态。虽然BAG 3 被证明对某些病毒的进入和复制有积极影响,我们发现, EBOV和MARV VP 40的PPxY基序与BAG 3的单个N-末端WW-结构域导致了一个 EBOV和MARV VP 40病毒样颗粒(VLP)以及VSV的排出意外减少 作为功能性EBOV替代物的重组病毒,因为它们被基因工程化, 表达EBOV VP 40 WT或突变体L-结构域代替VSV M的L-结构域。我们假设 在丝状病毒感染后诱导BAG 3表达,并且BAG 3靶向VP 40以去除 和/或从质膜上的出芽位点隔离。我们将使用严格的多方面 研究BAG 3破坏病毒颗粒外出的机制的方法,从而提供了新的 深入了解CASA作为一种新型和特异性宿主防御策略的潜在作用,以抵消 的VP 40,以促进有效的出口和病毒颗粒的传播。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RONALD N HARTY其他文献

RONALD N HARTY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RONALD N HARTY', 18)}}的其他基金

Role of Host Filamin Proteins in Regulating Filovirus Entry and Egress
宿主细丝蛋白在调节丝状病毒进入和排出中的作用
  • 批准号:
    10644499
  • 财政年份:
    2023
  • 资助金额:
    $ 24.64万
  • 项目类别:
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
针对严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的面向宿主的疗法的开发,
  • 批准号:
    10688262
  • 财政年份:
    2022
  • 资助金额:
    $ 24.64万
  • 项目类别:
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
针对严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的面向宿主的疗法的开发,
  • 批准号:
    10545109
  • 财政年份:
    2022
  • 资助金额:
    $ 24.64万
  • 项目类别:
Role of Host Angiomotin as a Central Regulator of Filovirus Egress and Dissemination
宿主血管动蛋白作为丝状病毒排出和传播的中央调节剂的作用
  • 批准号:
    10380684
  • 财政年份:
    2021
  • 资助金额:
    $ 24.64万
  • 项目类别:
Role of Host Angiomotin as a Central Regulator of Filovirus Egress and Dissemination
宿主血管动蛋白作为丝状病毒排出和传播的中央调节剂的作用
  • 批准号:
    10217843
  • 财政年份:
    2021
  • 资助金额:
    $ 24.64万
  • 项目类别:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
针对出血热病毒的小分子疗法的开发
  • 批准号:
    10257889
  • 财政年份:
    2018
  • 资助金额:
    $ 24.64万
  • 项目类别:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
针对出血热病毒的小分子疗法的开发
  • 批准号:
    10368115
  • 财政年份:
    2018
  • 资助金额:
    $ 24.64万
  • 项目类别:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
针对出血热病毒的小分子疗法的开发
  • 批准号:
    10599837
  • 财政年份:
    2018
  • 资助金额:
    $ 24.64万
  • 项目类别:
DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS AGAINST RNA VIRUSES
针对 RNA 病毒的小分子疗法的开发
  • 批准号:
    8903846
  • 财政年份:
    2015
  • 资助金额:
    $ 24.64万
  • 项目类别:
Innate Immune Regulation of Intracellular Pathways Involved in Filovirus Budding
丝状病毒出芽涉及的细胞内途径的先天免疫调节
  • 批准号:
    8635498
  • 财政年份:
    2013
  • 资助金额:
    $ 24.64万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 24.64万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 24.64万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 24.64万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 24.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 24.64万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 24.64万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 24.64万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 24.64万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 24.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 24.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了